Despite pandemic, European VCs active in healthcare

20 May 2020
medicines_money_stock_large

While the COVID-19 pandemic has impacted us all in ways that were impossible to predict just a few months ago, it seems that venture capitalists are ploughing away, with a heavy focus on the healthcare sector, as revealed in a report from Optimum Strategic Communications.

The survey conducted in May 2020 includes responses from 24 of the most influential European Venture Capital (VC) groups, investing around 15.5 billion euros (~$17 billion) in aggregate in the Healthcare Sector. Of these, six have recently raised new funds totalling ~2 billion euros in 2019/20.

The survey findings show there is a substantial amount of money available for investment in European companies and investors are seeking and reviewing new opportunities. Crucially, the survey reveals how it is strategically important for companies to adapt to the new ‘virtual norm’ to ensure that they are communicating a strong and compelling investment story. Now more than ever, clear and open communication, local connections and investor syndicates will be in focus.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology